Review of Latest Guidelines on Quad Therapy in NDMM
Panelists discuss how quadruplet therapy has become the new benchmark for NDMM, offering deeper and more durable responses than previous triplet regimens.
Panelists discuss how updated guidelines emphasize the integration of quadruplet therapy as the new standard of care for newly diagnosed multiple myeloma (NDMM), highlighting its potential to improve depth of response and progression-free survival. They review recent data supporting the combination of daratumumab with standard triplet regimens and note how these regimens have become increasingly feasible due to better tolerability and supportive care advances. The discussion explores how real-world application of these therapies requires individualized consideration of comorbidities and patient goals. Panelists emphasize the need for multidisciplinary coordination when applying quadruplet-based regimens, given differences in access and patient preferences. They underscore that although triplet therapy remains effective, evidence suggests the fourth drug provides a measurable advantage in both minimal residual disease negativity and sustained response. They also reflect on how ongoing trials continue to refine the duration of therapy, maintenance strategies, and sequencing. Finally, they describe how emerging biomarkers may influence treatment decisions, positioning quadruplet therapy not only as a one-size-fits-all solution but as a foundation for precision-based management.
